Ocular Hypertension - Pipeline Review, H2 2018

Ocular Hypertension - Pipeline Review, H2 2018


  • Products Id :- GMDHC10731IDB
  • |
  • Pages: 130
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Ocular Hypertension-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension-Pipeline Review, H2 2018, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 9, 14, 2 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 5

Ocular Hypertension-Overview 6

Ocular Hypertension-Therapeutics Development 7

Ocular Hypertension-Therapeutics Assessment 16

Ocular Hypertension-Companies Involved in Therapeutics Development 25

Ocular Hypertension-Drug Profiles 35

Ocular Hypertension-Dormant Projects 112

Ocular Hypertension-Discontinued Products 114

Ocular Hypertension-Product Development Milestones 116

Appendix 125

List of Figures

Number of Products under Development for Ocular Hypertension, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Ocular Hypertension, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Ocular Hypertension-Pipeline by Aerie Pharmaceuticals Inc, H2 2018

Ocular Hypertension-Pipeline by Allergan Plc, H2 2018

Ocular Hypertension-Pipeline by Angelini Group, H2 2018

Ocular Hypertension-Pipeline by Can-Fite BioPharma Ltd, H2 2018

Ocular Hypertension-Pipeline by D. Western Therapeutics Institute Inc, H2 2018

Ocular Hypertension-Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Ocular Hypertension-Pipeline by Kowa Co Ltd, H2 2018

Ocular Hypertension-Pipeline by Laboratorios SALVAT SA, H2 2018

Ocular Hypertension-Pipeline by Laboratorios Sophia SA de CV, H2 2018

Ocular Hypertension-Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018

Ocular Hypertension-Pipeline by Neurim Pharmaceuticals Ltd, H2 2018

Ocular Hypertension-Pipeline by NicOx SA, H2 2018

Ocular Hypertension-Pipeline by Novartis AG, H2 2018

Ocular Hypertension-Pipeline by Ocular Therapeutix Inc, H2 2018

Ocular Hypertension-Pipeline by Santen Pharmaceutical Co Ltd, H2 2018

Ocular Hypertension-Pipeline by Senju Pharmaceutical Co Ltd, H2 2018

Ocular Hypertension-Pipeline by Shire Plc, H2 2018

Ocular Hypertension-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Ocular Hypertension-Pipeline by Sylentis SAU, H2 2018

Ocular Hypertension-Pipeline by Taejoon Pharm Co Ltd, H2 2018

Ocular Hypertension-Dormant Projects, H2 2018

Ocular Hypertension-Dormant Projects, H2 2018 (Contd..1), H2 2018

Ocular Hypertension-Discontinued Products, H2 2018

Ocular Hypertension-Discontinued Products, H2 2018 (Contd..1), H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Aerie Pharmaceuticals Inc

Allergan Plc

Angelini Group

Can-Fite BioPharma Ltd

D. Western Therapeutics Institute Inc

Ironwood Pharmaceuticals Inc

Kowa Co Ltd

Laboratorios SALVAT SA

Laboratorios Sophia SA de CV

Lee's Pharmaceutical Holdings Ltd

Neurim Pharmaceuticals Ltd

NicOx SA

Novartis AG

Ocular Therapeutix Inc

Santen Pharmaceutical Co Ltd

Senju Pharmaceutical Co Ltd

Shire Plc

Sun Pharma Advanced Research Company Ltd

Sylentis SAU

Taejoon Pharm Co Ltd

Ocular Hypertension Therapeutic Products under Development, Key Players in Ocular Hypertension Therapeutics, Ocular Hypertension Pipeline Overview, Ocular Hypertension Pipeline, Ocular Hypertension Pipeline Assessment

select a license
Single User License
USD 2000 INR 137800
Site License
USD 4000 INR 275600
Corporate User License
USD 6000 INR 413400

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com